CervoMed Stock Price, News & Analysis

CervoMed (NASDAQ: CRVO), a clinical stage company focused on neurologic disorder treatments, will present new data from its Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies (DLB) at AAIC 2025.

The company will host a conference call on July 28, 2025, at 8:00 AM ET to discuss primary endpoint results at 32-weeks from the Extension phase. Investors can access the webcast through the company's website, with domestic participants dialing 1-877-425-9470 and international participants dialing 1-201-389-0878 using code 13755139.

CervoMed (NASDAQ: CRVO), a clinical stage company specializing in age-related neurologic disorders, will present late-breaking research at the Alzheimer's Association® International Congress (AAIC) 2025 in Toronto from July 27-31, 2025.

The company will showcase results from their RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) through two presentations: an in-person poster discussing effects on clinical progression in DLB patients without Alzheimer's disease co-pathology, and a virtual presentation examining the impact of AD co-pathology on treatment response.

CervoMed Inc. (NASDAQ: CRVO) has appointed Marco Verwijs, PhD as Executive Vice President of Technical Operations to lead their Chemistry, Manufacturing, and Controls division. Dr. Verwijs, formerly Chief Technical Officer at Adipo Therapeutics, brings extensive experience in drug development from pre-clinical through commercial stages. His appointment comes as CervoMed prepares for Phase 3 trials of neflamapimod in dementia with Lewy Bodies (DLB) scheduled for mid-2026. The company granted Dr. Verwijs stock options for 54,000 shares at $7.74 per share, vesting over three years, as an inducement for joining the company.

CervoMed (NASDAQ: CRVO) reported its Q1 2025 financial results and provided updates on its drug development programs. The company highlighted positive 16-week results from the extension phase of their Phase 2b RewinD-LB trial for neflamapimod in treating dementia with Lewy bodies (DLB). The trial showed significant improvements in clinical progression measures, with plans to initiate Phase 3 trials in mid-2026. The company ended Q1 with $35.2 million in cash, down from $38.9 million in December 2024. Financial results showed grant revenue of $1.9 million, R&D expenses of $4.8 million (up from $2.8 million), and a net loss of $4.9 million (increased from $2.5 million). CervoMed is also expanding its drug development pipeline with new Phase 2a trials for primary progressive aphasia and ischemic stroke recovery.

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company specializing in treatments for age-related neurologic disorders, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place in New York on May 20, 2025.

Company management will engage in a fireside chat scheduled from 5:00 to 5:30 PM ET and will also conduct one-on-one investor meetings. The fireside chat will be available via webcast through the company's website and a dedicated event platform.

CervoMed Inc. (NASDAQ: CRVO) announced positive results from the Extension phase of their Phase 2b RewinD-LB study of neflamapimod for treating dementia with Lewy bodies (DLB). The study showed that neflamapimod, when administered with New Capsules achieving target plasma concentrations, significantly slowed clinical progression compared to controls.

Key findings include:

• Improvement in Clinical Dementia Rating Sum of Boxes (CDR-SB) with New Capsules vs Old Capsules (p<0.001) and vs placebo (p=0.003)
• Mean improvement of 0.73 points with New Capsules compared to Old Capsules
• 40% lower rate of clinical worsening in New Capsule recipients
• Improved outcomes in Alzheimer's Disease Cooperative Study (ADCS-CGIC)
• Reduced incidence of falls (4% vs 15.2%) with New Capsules

The results will be presented at the AD/PD™ 2025 conference on April 5, 2025, demonstrating proof-of-concept for neflamapimod as a DLB treatment.

CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced an upcoming oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases (AP/PD™) in Vienna, Austria on April 5, 2025.

The presentation will focus on detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). The presentation will be delivered by CEO John Alam, MD, and Stephen Gomperts, MD, PhD, from Harvard Medical School and Massachusetts General Hospital.

CervoMed (NASDAQ: CRVO) has reported its Q4 and full-year 2024 financial results, highlighting positive 16-week results from the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB). The trial showed significant improvements in the primary outcome measure.

Financial highlights include:

• Cash position of $38.9 million as of December 31, 2024 (up from $7.8M in 2023)
• Grant revenue of $9.7 million for 2024 (up from $7.1M in 2023)
• R&D expenses increased to $18.8 million (from $8.4M in 2023)
• Net loss of $16.3 million for 2024

The company plans to initiate a Phase 3 trial in mid-2026 and expects to report 32-week extension phase results in H2 2025. Current cash runway extends into mid-2026.

CervoMed (NASDAQ: CRVO) has announced positive results from the 16-week extension phase of its Phase 2b RewinD-LB study for neflamapimod in treating dementia with Lewy bodies (DLB). The new batch of drug capsules showed significant improvements compared to both old capsules and placebo:

Key findings include:

• Improved Clinical Dementia Rating Sum of Boxes (CDR-SB) scores (p<0.001 vs. old capsules; p=0.003 vs. placebo)
• Better performance on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (p=0.035)
• Lower incidence of falls (7.4% vs. 14.5% for old capsules)
• Higher plasma drug concentrations (5.1 vs. 4.0 ng/mL, p=0.03)

The study involved 149 participants, with 94 receiving the new capsules and 55 receiving old capsules. The results suggest neflamapimod's potential to fundamentally change DLB treatment, particularly significant as no FDA-approved drugs currently exist for DLB management in the U.S.